RNA therapeutics are a rapidly growing class of medicines that use RNA molecules to regulate, replace, or correct biological processes. Unlike traditional small-molecule drugs that mainly target proteins, RNA-based approaches can directly control gene expression, offering new ways to treat previously difficult-to-target diseases.
Major types of RNA therapeutics
1. mRNA therapeutics
- Deliver messenger RNA to cells to produce a desired protein.
- Best known from mRNA COVID-19 vaccines.
- Expanding into:
- cancer vaccines
- protein replacement therapies
- regenerative medicine
2. siRNA (small interfering RNA) therapeutics
- Use RNA interference (RNAi) to selectively silence specific genes.
- siRNA guides the Argonaute 2 protein complex to degrade target mRNA.
- Applications include reducing disease-causing proteins in:
- genetic disorders
- liver diseases
- cardiovascular diseases
3. Antisense oligonucleotides (ASOs)
- Short synthetic RNA/DNA-like molecules that bind target RNA and alter its stability or processing.
- Used for diseases caused by abnormal gene expression or splicing defects.
4. microRNA-based therapeutics
- Mimic or inhibit natural regulatory RNAs that control many genes.
- Being explored in cancer and fibrosis.
Key challenges
Despite great potential, RNA therapeutics face several engineering challenges:
- Delivery: Getting RNA molecules into the correct tissues and cells.
- Stability: Protecting RNA from degradation.
- Immune activation: Avoiding unwanted inflammatory responses.
- Specificity: Minimizing off-target effects.
Technologies such as Lipid nanoparticles, chemical RNA modifications, and improved targeting molecules are helping overcome these barriers.